Novartis announces 20% average reduction in price of malaria drug Coartem®
Novartis has announced a 20% average reduction in the price of Coartem® tablets (artemether/lumefantrine 20 mg/120 mg), the state-of-the-art artemisinin-based combination treatment (ACT) for malaria. Starting this Friday, which is World Malaria Day, this price reduction will increase access to Coartem for millions of malaria patients, especially children in low income regions of Africa.
Read more ...
The Medicines Company Reports First Quarter 2008 Financial Results
The Medicines Company (NASDAQ: MDCO) today announced its financial results for the first quarter of 2008. Financial highlights for the first quarter of 2008:
Net revenue increased by 19% to $79.4 million for the first quarter of 2008 from $66.6 million for the first quarter of 2007.
Environmentally Responsible Site to Significantly Increase Company's Presence in China
Genzyme Corp. (Nasdaq: GENZ) announced today that it will build a major new research and development center in Beijing. The initiative is an important element in Genzyme's ongoing global expansion and commitment to establishing a long-term presence in China.
Read more ...
Results from phase 2b "DEEP" study in severe pre-eclampsia
Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announces that its placebo-controlled phase 2b Digoxin Immune Fab (DIF) Efficacy Evaluation in Pre-eclampsia ("DEEP") study in severe pre-eclampsia has met one of its two primary endpoints.
Read more ...
Bayer Challenges Watson and Sandoz U.S. ANDA Filings on Yasmin®
Bayer confirmed that Bayer Schering Pharma AG and Bayer HealthCare Pharmaceuticals Inc. filed a patent infringement lawsuit in U.S. Federal Court in the Southern District of New York (New York) against Watson Pharmaceuticals, Inc., Watson Laboratories, Inc. and Sandoz, Inc.
Read more ...
FTY720, a novel oral therapy in development for multiple sclerosis
The investigational oral therapy FTY720 (fingolimod) continues to demonstrate sustained benefits in patients with multiple sclerosis (MS) after three years of treatment, according to new clinical data presented from an ongoing Phase II study extension[1].
Read more ...
GlaxoSmithKline and Regulus Therapeutics form strategic alliance
GlaxoSmithKline (GSK) and Regulus Therapeutics LLC (Regulus) announced a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.
Read more ...